Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously, lumbar fusion had been reported to be responsible for a rate of ASD as high as 28.6% at 5 years.
activ-L received FDA Premarket Approval in 2Q15 for treatment of 1-level lumbar degenerative disc disease.
Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously,...
Studies indicate that, at 5 years, the activ-L® Artificial Disc from Aesculap Implant Systems had a protective effect on the progression of degenerative disc disease at adjacent levels in 91.2% of patients. The data reiterates the role of lumbar total disc replacement in delaying the progression of adjacent segment disease (ASD).
Previously, lumbar fusion had been reported to be responsible for a rate of ASD as high as 28.6% at 5 years.
activ-L received FDA Premarket Approval in 2Q15 for treatment of 1-level lumbar degenerative disc disease.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
